BiotechTV - News

From Basel: TOLREMO Therapeutics is working on cancer resistance - the company believes is targeting CBP/p300 just stared phase 1 data at World Lung

Sep 29, 2026
Stefanie Fluckiger-Mangual, CEO of TOLREMO Therapeutics, develops therapies against cancer treatment resistance. She explains the company’s distinct CBP/p300 inhibitor chemistry and encouraging phase 1 findings in resistant lung cancer. The conversation explores drug-tolerant cancer states, TT125-802’s safety profile, potential combinations with osimertinib, and TOLREMO’s broader plans in solid tumors and multiple myeloma.
Ask episode
AI Snips
Chapters
Transcript
Episode notes
INSIGHT

Cancer Resistance Outlasts Effective Treatments

  • Cancer treatment often fails because tumors adapt, not because effective therapies are unavailable.
  • Stefanie Fluckiger-Mangual began studying this resistance mechanism at ETH Zurich 15 years ago.
INSIGHT

TOLREMO Found CBP Through Phenotypic Screening

  • TOLREMO and Cellcentric target the same CBP/p300 bromodomain, but their chemistries differ substantially.
  • TOLREMO discovered CBP through a target-agnostic phenotypic screen rather than designing a conventional CBP inhibitor.
INSIGHT

A Cleaner Safety Profile May Expand CBP Therapy

  • First-generation CBP inhibitors showed efficacy but were limited by severe dose-limiting thrombocytopenia.
  • TOLREMO's TT125802 produced no thrombocytopenia among 45 phase 1 patients.
Get the Snipd Podcast app to discover more snips from this episode
Get the app